Rajesh Malik

ORCID: 0000-0002-9661-9347
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lung Cancer Research Studies
  • Advanced Breast Cancer Therapies
  • Aortic aneurysm repair treatments
  • Neuroendocrine Tumor Research Advances
  • Cardiac, Anesthesia and Surgical Outcomes
  • Aortic Disease and Treatment Approaches
  • Cancer Treatment and Pharmacology
  • Vascular Procedures and Complications
  • Cancer therapeutics and mechanisms
  • Cerebrovascular and Carotid Artery Diseases
  • Cardiovascular Health and Disease Prevention
  • Neutropenia and Cancer Infections
  • Infectious Aortic and Vascular Conditions
  • Cell Adhesion Molecules Research
  • HER2/EGFR in Cancer Research
  • Cancer, Hypoxia, and Metabolism
  • Venous Thromboembolism Diagnosis and Management
  • Renal and Vascular Pathologies
  • Peripheral Artery Disease Management
  • Sarcoma Diagnosis and Treatment
  • Central Venous Catheters and Hemodialysis
  • Peptidase Inhibition and Analysis
  • Chronic Lymphocytic Leukemia Research
  • Gastrointestinal disorders and treatments
  • Cancer Genomics and Diagnostics

Westmead Hospital
2025

Western Sydney University
2025

The University of Sydney
2025

Cornell University
2021-2024

Weill Cornell Medicine
2021-2024

All India Institute of Medical Sciences Bhopal
2018-2024

ICMR National Institute for Research in Environmental Health
2023

Indian Council of Medical Research
2023

Wyckoff Heights Medical Center
2023

G1 Therapeutics (United States)
2015-2022

Airway concentrations of many reactive nitrogen and oxygen species are high in asthma. The stability bioactivities these pH-dependent; however, the pH airway during acute asthma has not previously been studied. As with gastric urinary acidification, asthmatic acidification could be expected dramatically to alter bioactivities/cytotoxicities endogenous oxides. Here, we demonstrate that deaerated exhaled vapor condensate is over two log orders lower patients (5.23 ± 0.21, n = 22) than control...

10.1164/ajrccm.161.3.9911005 article EN American Journal of Respiratory and Critical Care Medicine 2000-03-01

Abstractpp125FAK is a tyrosine kinase that appears to regulate the assembly of focal adhesions and thereby promotes cell spreading on extracellular matrix. In some cells, C terminus pp125FAK expressed as separate protein, pp41/43FRNK. We have previously shown overexpression pp41/43FRNK inhibits phosphorylation paxillin and, in addition, delays adhesion assembly. Thus, functions negative inhibitor signaling provides tool dissect mechanism by which spreading. report here inhibitory effects...

10.1128/mcb.17.12.6906 article EN Molecular and Cellular Biology 1997-12-01

Chemotherapy-induced damage of hematopoietic stem and progenitor cells (HSPC) causes multi-lineage myelosuppression. Trilaciclib is an intravenous CDK4/6 inhibitor in development to proactively preserve HSPC immune system function during chemotherapy (myelopreservation). Preclinically, trilaciclib transiently maintains G1 arrest protects them from damage, leading faster recovery enhanced antitumor immunity.

10.1093/annonc/mdz278 article EN cc-by-nc Annals of Oncology 2019-08-23

The concomitant use of CDK4/6 inhibitors with cytotoxic agents may prevent chemotherapy-induced bone marrow exhaustion in cancer patients.

10.1126/scitranslmed.aal3986 article EN Science Translational Medicine 2017-04-26

PURPOSE: There are a variety of solid tumors in which alternative chromosomal translocations generate related fusion products. In alveolar rhabdomyosarcoma and synovial sarcoma, these variant fusions have been found to major clinical significance. We investigated whether the two gene products, EWS-FLI1 EWS-ERG, define different subsets within Ewing's sarcoma family tumors. PATIENTS AND METHODS: selected 30 cases with EWS-ERG 106 fusion. Clinical data were obtained for each case compared...

10.1200/jco.1999.17.6.1809 article EN Journal of Clinical Oncology 1999-06-01

Fifty-nine evaluable patients under 65 years of age with measurable metastatic breast cancer and without prior chemotherapy were randomly assigned to treatment fluorouracil, Adriamycin (Adria Laboratories, Columbus, OH), cyclophosphamide (FAC) at standard or high doses (100% 260% higher than FAC) following a dose escalation schedule. Patients randomized the high-dose FAC received first three cycles therapy within protected environment. Subsequent for this group administered in an ambulatory...

10.1200/jco.1987.5.3.354 article EN Journal of Clinical Oncology 1987-03-01

Background Combination treatment with chemotherapy and immune checkpoint inhibitors (ICIs) has demonstrated meaningful clinical benefit to patients. However, chemotherapy-induced damage the system can potentially diminish efficacy of chemotherapy/ICI combinations. Trilaciclib, a highly potent, selective reversible cyclin-dependent kinase 4 6 (CDK4/6) inhibitor in development preserve hematopoietic stem progenitor cells function during chemotherapy, proof concept recent trials. Furthermore,...

10.1136/jitc-2020-000847 article EN cc-by-nc Journal for ImmunoTherapy of Cancer 2020-10-01

To investigate the activity and safety of oral talactoferrin (TLF) in patients with stages IIIB to IV non-small-cell lung cancer (NSCLC) for whom one or two prior lines systemic anticancer therapy had failed.Patients (n = 100) were randomly assigned receive either TLF (1.5 g 15 mL phosphate-based buffer) placebo (15 twice per day addition supportive care. Oral was administered a maximum three 14-week cycles dosing 12 consecutive weeks followed by 2 off. The primary objective overall survival...

10.1200/jco.2010.34.4127 article EN Journal of Clinical Oncology 2011-10-04

Abstract Background Supportive care interventions used to manage chemotherapy‐induced myelosuppression (CIM), including granulocyte colony‐stimulating factors (G‐CSFs), erythropoiesis‐stimulating agents (ESAs), and red blood cell (RBC) transfusions, are burdensome patients associated with greater costs health systems. We evaluated the utilization of supportive their relationship myeloprotective agent, trilaciclib. Methods Data were pooled from three independent randomized phase 2 clinical...

10.1002/cam4.4089 article EN cc-by Cancer Medicine 2021-08-18

Background Trauma patients may require activation of an emergent massive transfusion protocol (MTP). Several decision aids are designed to predict requirements but have not been widely studied in the Australasian setting. Methods Commonly used MTP were assessed for accuracy injured at urban Level 1 trauma centre. Consecutive cases prospectively enrolled a complete registry thromboelastogram assays patients. Analysis was undertaken using receiver operating characteristic (ROC) curves,...

10.1097/mbc.0000000000001338 article EN Blood Coagulation & Fibrinolysis 2025-01-02
Suresh S. Ramalingam Jeffrey Crawford Alex Y. Chang C. Manegold Román Pérez-Soler and 95 more Jean-Yves Douillard Nicholas Thatcher Fabrice Barlési Taofeek K. Owonikoko Y. Wang Philippe Pultar Jing Zhu Rajesh Malik Giuseppe Giaccone Stephen Della‐Fiorentina Stephen Begbie Ross Jennens Joshua Dass K. Pittman N.M. Ivanova Tatyana Koynova Petar Petrov Antoaneta Tomova Valentina Tzekova Félix Couture Vera Hirsh Ronald L. Burkes Randeep Sangha Miloslav Ambruš Terezie Janaskova J Musil J. Novotny Petr Zatloukal Jitka Jakesova Kamil Klenha Jaromı́r Roubec J Vaňásek Jérôme Fayette Fabrice Barlési Jaafar Bennouna-Louridi C. Chouaïd Julien Mazières H. Vallerand G. Robinet P.-J. Souquet D. Spaëth Roland Schött H. Léna Y. Martinet Claude El Kouri Nathalie Baize Arnaud Scherpereel O. Molinier F. Fuchs K. Josten C. Manegold Norbert Marschner Folker Schneller Tobias R. Overbeck Michael Thomas Joachim von Pawel Martin Reck Wolfgang Schuette Volker Hagen Claus-Peter Schneider V. Georgoulias Ioannis Varthalitis Kostas Zarogoulidis K. Syrigos Christos N. Papandreou Csaba Böcskei Eszter Csánky Erzsébet Juhász György Losonczy Z. Mark István Molnár Zsolt Pápai-Székely S. Tehenes Ilona Vinkler Sachin Almel Ashish Bakshi Shailesh Bondarde A Maru Ashutosh Pathak R.M. Pedapenki Krishna Prasad S.V.S.S. Prasad Nalini Kilara D. Gorijavolu Chetan Deshmukh S.K.P. John Lalit Mohan Sharma D. Amoroso Emilio Bajetta Paolo Bidoli Andrea Bonetti Filippo de Marinis Massimo Di Maïo Rodolfo Passalacqua Stefano Cascinu

10.1093/annonc/mdt371 article EN publisher-specific-oa Annals of Oncology 2013-09-20

Interaction of the cell surface integrin receptors with extracellular matrix proteins results in activation intracellular signaling pathways, including p42/p44 mitogen-activated protein kinases. The tyrosine kinase focal adhesion kinase, or FAK, is linked to and interacts several molecules involved signal transduction. Here we report that exposure fibroblast cells activates p70/p85 ribosomal S6 (S6K) pathway a ligand dependent manner. Treatment inhibitors phosphatidylinositol 3-kinase, FRAP...

10.1074/jbc.271.47.29785 article EN cc-by Journal of Biological Chemistry 1996-11-01

Galectin-1, the prototype of a family β-galactoside-binding proteins, has been implicated in wide variety biological processes. Data presented herein show that galectin-1 stimulates monocyte migration dose-dependent manner but is not chemotactic for macrophages. Galectin-1-induced chemotaxis blocked by lactose and inhibited an anti-galectin-1 antibody nonspecific antibodies. Furthermore, galectin-1-mediated was significantly MEK inhibitors rapid, time-dependent suggesting MAP kinase pathways...

10.1093/glycob/cwp077 article EN Glycobiology 2009-06-26

Introduction Non-alcoholic fatty liver disease (NAFLD) is the main cause of chronic worldwide. NAFLD refers to a group diseases that includes simple steatosis, nonalcoholic steatohepatitis, cirrhosis, and hepatocellular carcinoma. Unfortunately, there aren't many studies on conducted in India. The majority research involved specific populations, such as diabetics, pregnant women with gestational diabetes, obese or non-obese people. When current study was being planned, were few...

10.7759/cureus.33977 article EN Cureus 2023-01-19

Rapid stimulation of c-fos transcription by many agonists requires the serum response element (SRE), which binds at least two distinct nuclear proteins, p67SRF and p62TCF. Using protein extracts from 1321-N1 human astrocytoma cells, we investigated ligand-induced changes in binding these proteins to SRE probes. In cells mRNA expression can be induced epidermal growth factor (EGF) through kinase C-independent pathways phorbol esters C. We detected DNA-protein complexes that formed...

10.1016/s0021-9258(18)93013-9 article EN cc-by Journal of Biological Chemistry 1991-05-01

Abstract BACKGROUND. Talactoferrin (TLF), a recombinant form of human lactoferrin (hLF), is an immunomodulatory iron‐binding glycoprotein first identified in breast milk. Its functions include activation natural killer (NK) and lymphokine‐activated cells enhancement polymorphonuclear macrophage cytotoxicity. Studies animal models have shown promising anticancer activity, clinical antitumor activity has been observed nonsmall cell lung cancer other tumor types. The purpose the current study...

10.1002/cncr.23519 article EN Cancer 2008-05-16

Chondroid syringoma represents the cutaneous counterpart of mixed tumor (pleomorphic adenoma) salivary glands, therefore it is also termed "mixed tumour skin." It generally accepted that there are both eccrine and apocrine variants tumors skin. Malignant chondroid a malignant neoplasm very rarely encountered in radio-pathological clinical practice. Unlike benign variety which occurs most often on head neck, syringomas found trunk extremities. The usual presentation an asymptomatic...

10.4103/2229-5178.115533 article EN cc-by-nc-sa Indian Dermatology Online Journal 2013-01-01

ADH-1 (Exherin™) is a pentapeptide, which competitively inhibits N-cadherin, resulting in vascular disruptive effect of tumor vasculature preclinical models. This study was designed to assess the toxicity and determine maximal tolerated dose (MTD). Patients Methods: Adult patients with advanced measurable solid tumors were stratified according their N-cadherin status. administered as short infusion, every six weeks. Assessment response done 6 PK parameters included: estimated volume...

10.2174/1574884711308010011 article EN Current Clinical Pharmacology 2013-01-01

Chemotherapy-induced myelosuppression is an acute, dose-limiting toxicity of chemotherapy regimens used in the treatment extensive-stage small cell lung cancer (ES-SCLC). Trilaciclib protects haematopoietic stem and progenitor cells from chemotherapy-induced damage (myeloprotection). To assess totality myeloprotective benefits trilaciclib, including analysis several clinically relevant but low-frequency events, exploratory composite endpoint comprising five major adverse haematological...

10.1002/ijc.33705 article EN cc-by International Journal of Cancer 2021-06-10
Coming Soon ...